Evogene (NASDAQ: EVGN) reported Q4 EPS of ($0.07), $0.13 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $660 thousand versus the consensus estimate of $425 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.